Bandingkan Harga & Kinerja Organon Pharma Indonesia Tbk. (SCPI) vs Mizuho Leasing Indonesia Tbk. (VRNA)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Organon Pharma Indonesia Tbk. dan Mizuho Leasing Indonesia Tbk.: Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M), sedangkan Mizuho Leasing Indonesia Tbk. diperdagangkan di Rp91 (kapitalisasi pasar 534,61 M, volume 24 jam 3,04 jt). Perbedaan utamanya: Mizuho Leasing Indonesia Tbk. jauh lebih besar — sekitar 5,1× kapitalisasi pasar Organon Pharma Indonesia Tbk.. Mana yang lebih baik tergantung tujuan investasimu.
| SCPI | VRNA | |
|---|---|---|
Kapitalisasi Pasar | 104,4 M | 534,61 M |
Volume | — | 3,04 jt |
Lot | — | 30,36 rb |
Perputaran | — | 276,96 jt |
Harga Rata-rata | — | 91,21 |
Nilai Transaksi | — | 276,96 jt |
Harga Ekuilibrium Indikatif | — | 91 |
Volume Ekuilibrium Indikatif | — | 8,99 rb |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →Tentang Mizuho Leasing Indonesia Tbk.
PT Verena Oto Finance (the Company) was established under its original name of PT Maxima Perdana Finance base on notarial deed No.43 of Mrs Sri Nanning, S.H, dated on Jul 21, 1993. The Companys articles of association has been amended several times, most recently by notarial deed No. 32 of Fathiah Helmi, S.H., dated Mar 26, 2007, concerning among others, the change in the Companys name, increase authorized, change in par value, and increase paid-up capital.
Selengkapnya di halaman VRNA →
